Adolor Corporation to Host Investor Conference Call to Discuss Second Quarter 2011 Results

-- Conference Call Scheduled for July 27, 2011, 8:30 a.m. U.S. EDT --

EXTON, Pa.--(BUSINESS WIRE)-- Adolor Corporation (NasdaqGM: ADLR) today announced that it will hold a conference call at 8:30 a.m. EDT on Wednesday, July 27, 2011, to discuss second quarter 2011 results.

To participate in the audio portion and have the opportunity to pose questions, dial 866-383-8119 for domestic callers or 617-597-5344 for international callers, and enter Conference ID # 55315042. Investors also can listen to the call live by logging on to the Company’s website at www.adolor.com and clicking on “Investor Insights,” then "Calendar of Events."

A replay of the call will be available beginning approximately two hours after the event. To listen to a replay of the conference call, dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter Conference ID # 89375697 or listen via Adolor’s website. The replay will be available for one week.

About Adolor

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain and pain management products.

Adolor’s first approved product in the United States is ENTEREG® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the E.A.S.E.® Program. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com. The Company currently co-promotes ENTEREG in collaboration with GSK.

The Company's research and development pipeline includes: ADL5945 and ADL7445, novel mu opioid receptor antagonists undergoing clinical development for chronic OIC; and several earlier-stage compounds under development for the management of pain and CNS disorders.

For more information, visit www.adolor.com.



CONTACT:

Adolor Corporation
Stephen W. Webster
Senior Vice President, Finance and CFO
484-595-1500

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Professional Services  Finance  Research  Science

MEDIA:

Suggested Articles

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.